Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 7/20 | 0.54 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL748316 | 0.92 | NFKB1 (0.52) | ABCB1ABCG2MAPTNPSR1TDP1 | |
| SCHEMBL744994 | 0.91 | MAPT (0.49) | ABCB1CXCL12ABCG2MAPTNPSR1 | |
| SCHEMBL749682 | 0.91 | TDP1 (0.56) | ABCB1CXCL12ABCG2MAPTNPSR1 | |
| SCHEMBL13075708 | 0.91 | ABCB1 (0.48) | ABCB1CXCL12CXCR4ABCG2MAPT | |
| SCHEMBL743874 | 0.90 | ABCB1 (0.57) | ABCB1CXCL12ABCG2MAPTNPSR1 | |
| SCHEMBL20858989 | 0.90 | MAPT (0.48) | ABCB1ABCG2MAPTNPSR1TDP1 | |
| SCHEMBL744745 | 0.90 | CXCL12 (0.49) | ABCB1CXCL12ABCG2MAPTNPSR1 | |
| SCHEMBL764043 | 0.90 | MAPT (0.61) | ABCB1MAPTNPSR1MAOBMAOA | |
| SCHEMBL7033020 | 0.90 | MAPT (0.61) | ABCB1MAPTNPSR1MAOBMAOA | |
| SCHEMBL13075713 | 0.89 | ABCB1 (0.47) | ABCB1ABCG2MAPTNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429292-B1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | GEORGIA STATE UNIV RESEARCH FOUNDATION (US) | 2019-04-03 | — | — | EP | claimed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | claimed |
| EP-2429292-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | Georgia State University Research Foundation, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010129858-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | WO | claimed |
| EP-2429292-B1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | GEORGIA STATE UNIV RESEARCH FOUNDATION (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
| EP-2429292-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | Georgia State University Research Foundation, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010129858-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | ABCB1 2307/4885CXCL12 2187/4885CXCR4 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.